Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.85 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 3/20 | 0.80 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.80 |
| ▸ | AURKA | O14965 | 2/20 | 0.80 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.80 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366095 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Dodecanoyl-Coa SCHEMBL4309283 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL1756475 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Decanoyl-Coa SCHEMBL24667667 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL1129961 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Octanoyl-Coa SCHEMBL24667663 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL11027446 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Octanoyl-Coa SCHEMBL2370508 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20970006 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| Dodecanoyl-Coa SCHEMBL187868 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121914887-A | Recombinant lipolytica saccharomyces cerevisiae engineering strain for producing nervonic acid and application | 江南大学 | 2026-04-24 | — | — | CN | disclosed |
| EP-4622992-A1 | COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY | Amyndas Pharmaceuticals US LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12208125-B2 | Stable dry powders and emulsions containing probiotics | VIRUN, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12178908-B2 | Tolerogenic liposomes and methods of use thereof | AnTolRx, Inc. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240287555-A1 | METHODS AND YEAST CELLS FOR PRODUCTION OF DESATURATED COMPOUNDS | FMC Agricultural Solutions A/S (DK) | 2024-08-29 | — | — | US | disclosed |
| US-20240263200-A1 | PRODUCTION OF SATURATED FATS IN MICROBES | Nourish Ingredients Pty Ltd (AU) | 2024-08-08 | — | — | US | disclosed |
| CN-118251135-A | Production of saturated fat in microorganisms | 营养成分私人有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024110878-A1 | COMPSTATIN ANALOGS FOR VECTOR-BASED THERAPY | AMYNDAS PHARMACEUTICALS US LLC (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4363561-A1 | METHODS AND YEAST CELLS FOR PRODUCTION OF DESATURATED COMPOUNDS | FMC Agricultural Solutions A/S (DK) | 2024-05-08 | — | — | EP | disclosed |
| CN-117916363-A | Method for producing desaturated compounds and yeast cells | 富美实农业解决方案公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20220387398-A1 | IMMUNE TOLERIZATION AGENTS AND POTENTIATORS | ANTOLRX INC (US) | 2022-12-08 | — | — | US | disclosed |
| US-11491194-B2 | Stable dry powders and emulsions containing probiotics | VIRUN, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220280598-A1 | COMPLEMENT INHIBITOR DOSING REGIMENS | APELLIS PHARMACEUTICALS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3999054-A1 | IMMUNE TOLERIZATION AGENTS AND POTENTIATORS | Antolrx, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3996744-A1 | VIRAL VECTOR THERAPY | Apellis Pharmaceuticals, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| EP-3976802-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | Selecta Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20120191434-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR MODELING CHINESE HAMSTER OVARY (CHO) CELL METABOLISM | GT LIFE SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280598-A1 | COMPLEMENT INHIBITOR DOSING REGIMENS | C5, CFH, C1QBP | NAA50 2149/4885CHAT 3120/4885EP300 1858/4885 |
| US-11491194-B2 | Stable dry powders and emulsions containing probiotics | FABP2, FABP6, MUC1 | NAA50 844/4885CHAT 3030/4885EP300 2569/4885 |
| US-12208125-B2 | Stable dry powders and emulsions containing probiotics | FABP2, FABP6, MUC1 | NAA50 844/4885CHAT 3030/4885EP300 2569/4885 |
| US-12178908-B2 | Tolerogenic liposomes and methods of use thereof | CD47, TSLP, LY96 | NAA50 4242/4885CHAT 4406/4885EP300 3425/4885 |
| US-20220387398-A1 | IMMUNE TOLERIZATION AGENTS AND POTENTIATORS | HLA-DRB1, CD74, NFATC1 | NAA50 2153/4885CHAT 4741/4885EP300 1333/4885 |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | CFH, CFB, HAVCR2 | NAA50 2381/4885CHAT 917/4885EP300 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.